

Review Form 1.6

| | |
|--------------------------|---|
| Journal Name: | Journal of Pharmaceutical Research International |
| Manuscript Number: | Ms_JPRI_85501 |
| Title of the Manuscript: | MONOCLONAL ANTIBODIES: USAGE IN THE TREATMENT OF COVID-19 INFECTION |
| Type of the Article | Review Article |

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journaljpri.com/index.php/JPRI/editorial-policy>)

PART 1: Review Comments

| | Reviewer's comment | Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here) |
|-------------------------------------|---|---|
| Compulsory REVISION comments | 1-Please explain more about the effect of these monoclonal antibodies on different variant of Covid-19 like Omicron variant | |
| Minor REVISION comments | 1-Please add effect of other monoclonal antibodies like Bebtelovimab, tixagevimab and cilgavimab in the treatment of Covid-19 | |
| Optional/General comments | | |

PART 2:

| | Reviewer's comment | Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here) |
|--|---|---|
| Are there ethical issues in this manuscript? | (If yes, Kindly please write down the ethical issues here in details) | |

Reviewer Details:

| | |
|----------------------------------|--|
| Name: | Sahand Mohammadzadeh |
| Department, University & Country | Shiraz University of Medical Science, Iran |